European Journal of Cancer
Volume 46, Issue 1 , Pages 198-206 , January 2010

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

  • Vanesa Gregorc

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Giovanni Citterio

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Giordano Vitali

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Anna Spreafico

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Paola Scifo

      Affiliations

    • Department of Nuclear Medicine, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Anna Borri

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Giovanni Donadoni

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Gilda Rossoni

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Angelo Corti

      Affiliations

    • Tumor Biology and Vascular Targeting Unit, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Federico Caligaris-Cappio

      Affiliations

    • Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • Università Vita-Salute San Raffaele, Milan, Italy
    • ,
  • Alessandro Del Maschio

      Affiliations

    • Department of Radiology, Istituto Scientifico San Raffaele, Milan, Italy
    • Università Vita-Salute San Raffaele, Milan, Italy
    • ,
  • Antonio Esposito

      Affiliations

    • Department of Radiology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Francesco De Cobelli

      Affiliations

    • Department of Radiology, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Flavio Dell’Acqua

      Affiliations

    • Department of Nuclear Medicine, Istituto Scientifico San Raffaele, Milan, Italy
    • ,
  • Antonella Troysi

      Affiliations

    • MolMed, Milan, Italy
    • ,
  • Paolo Bruzzi

      Affiliations

    • Clinical Epidemiology Unit, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    • ,
  • Antonio Lambiase

      Affiliations

    • MolMed, Milan, Italy
    • ,
  • Claudio Bordignon

      Affiliations

    • Università Vita-Salute San Raffaele, Milan, Italy
    • MolMed, Milan, Italy
    • Corresponding Author InformationCorresponding author: Address: Via Olgettina, 58, 20132 Milan, Italy. Tel.: +39 02 2643 2351; fax: +39 02 2643 2285.

Received 1 September 2009 ,Revised 18 September 2009 ,Accepted 2 October 2009.

References 

  1. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA. 1975;72:3666–3670
  2. Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006;6:6
  3. Creaven PJ, Brenner DE, Cowens JW, et al. A phase I clinical trial of recombinant human tumour necrosis factor given daily for five days. Cancer Chemother Pharmacol. 1989;23:186–191
  4. Gamm H, Lindemann A, Mertelsmann R, et al. Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer. 1991;27:856–863
  5. Kimura K, Taguchi T, Urushizaki I, et al. Phase I study of recombinant human tumour necrosis factor. Cancer Chemother Pharmacol. 1987;20:223–229
  6. Mittelman A, Puccio C, Gafney E, et al. A phase I pharmacokinetic study of recombinant human tumour necrosis factor administered by a 5-day continuous infusion. Invest New Drugs. 1992;10:183–190
  7. Schwartz JE, Scuderi P, Wiggins C, et al. A phase I trial of recombinant tumour necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy. 1989;1:207–214
  8. Wiedenmann B, Reichardt P, Rath U, et al. Phase-I trial of intravenous continuous infusion of tumour necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol. 1989;115:189–192
  9. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumour necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14:2653–2665
  10. Alexander HR, Brown CK, Bartlett DL, et al. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumour necrosis factor-independent mechanisms. Clin Cancer Res. 1998;4:2357–2362
  11. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumour immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18:1185–1190
  12. Corti A, Ponzoni M. Tumour vascular targeting with tumour necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci. 2004;1028:104–112
  13. Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem. 2002;277:47891–47897
  14. Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumour vessels, epithelia, and myeloid cells. Cancer Res. 2002;62:867–874
  15. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumours by vascular targeting and barrier alteration. J Clin Invest. 2002;110:475–482
  16. van Laarhoven H, Fiedler W, Desar I, et al. Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumours (EORTC 16041). J Clin Oncol. 2008;26:158s;[abstr. 3521]
  17. Parker GJ, Suckling J, Tanner SF, et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging. 1997;7:564–574
  18. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  19. Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumour perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag. 2004;23:65–83
  20. Cooney MM, van Heeckeren W, Bhakta S, et al. Drug insight: vascular disrupting agents and angiogenesis–novel approaches for drug delivery. Nat Clin Pract Oncol. 2006;3:682–692
  21. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov. 2002;1:415–426
  22. Bocci G, Man S, Green SK, et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004;64:6616–6625
  23. Gaya AM, Rustin GJ. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol). 2005;17:277–290
  24. Fraker DL, Alexander HR, Pass HI. Biologic therapy with TNF: systemic administration and isolation-perfusion. In:  De Vita V,  Hellman S,  Rosenberg S editor. Biologic therapy of cancer: principles and practice. Philadelphia, Pennsylvania: JB Lippincott Co.; 1995;p. 329–345
  25. Lienard D, Eggermont AM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 1994;4(Suppl. 1):21–26
  26. Aderka D, Sorkine P, Abu-Abid S, et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. J Clin Invest. 1998;101:650–659
  27. Jackson A, O’Connor JPB, Parker GJM, et al. Imaging tumour vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res. 2007;13(12):3449–3459

PII: S0959-8049(09)00730-8

doi: 10.1016/j.ejca.2009.10.005

European Journal of Cancer
Volume 46, Issue 1 , Pages 198-206 , January 2010

Article Tools

* Image Usage & Resolution